Case ReportPremedication with fast-acting OXYCODONE HYDROCHLORIDE (cas 124-90-3) hydrate effectively reduced oxaliplatin-induced severe vascular pain
-
Add time:09/08/2019 Source:sciencedirect.com
Oxaliplatin is a platinum-based chemotherapeutic agent that holds a prominent position in the treatment of colorectal and gastric cancers. However, severe oxaliplatin-related vascular pain can be problematic for patients. Here we describe seven patients who experienced severe vascular pain caused by oxaliplatin administration. All seven patients were treated with capecitabine and oxaliplatin or capecitabine plus oxaliplatin with bevacizumab as an adjuvant or a treatment for recurrent colorectal cancer, respectively. Patients experienced intolerable vascular pain during oxaliplatin administration, which continued for several days. Moreover, vascular pain also induced insomnia and appetite loss in all patients. We recommended implantation of a central venous (CV) port to the patients; however, all patients declined this treatment. In addition, various known countermeasures were taken, but were ineffective. Therefore, patients were orally administered OXYCODONE HYDROCHLORIDE (cas 124-90-3) hydrate (Oxinorm®) 45 min prior to oxaliplatin administration. This pretreatment successfully reduced vascular pain and improved subsequent chemotherapy. Oxinorm® is a fast-acting opioid that can be an effective and practical option for severe vascular pain induced by oxaliplatin. The present report is the first description that emphasizes the usefulness of Oxinorm® to overcome the vascular pain induced by administration of oxaliplatin via a peripheral vein.
We also recommend Trading Suppliers and Manufacturers of OXYCODONE HYDROCHLORIDE (cas 124-90-3). Pls Click Website Link as below: cas 124-90-3 suppliers
Prev:Short communicationDevelopmental characteristics of PICROTOXIN (cas 124-87-8)-induced convulsions in rats with genetic absence epilepsy
Next:Original research articlePharmacokinetics of OXYCODONE HYDROCHLORIDE (cas 124-90-3) and three of its metabolites after intravenous administration in Chinese patients with pain) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Original ReportSafety and Efficacy of Once-Daily Hydromorphone Extended-Release Versus Twice-Daily OXYCODONE HYDROCHLORIDE (cas 124-90-3) Controlled-Release in Chinese Patients With Cancer Pain: A Phase 3, Randomized, Double-Blind, Multicenter Study10/01/2019
- Research reportOxycodone suppresses the apoptosis of hippocampal neurons induced by oxygen-glucose deprivation/recovery through caspase-dependent and caspase-independent pathways via κ- and δ-opioid receptors in rats09/27/2019
- Oxycodone-like discriminative stimulus effects of fentanyl-related emerging drugs of abuse in mice09/26/2019
- Prophylactic vaccination protects against the development of oxycodone self-administration09/25/2019
- Full length articleComparison of the antinociceptive profiles of morphine and oxycodone in two models of inflammatory and osteoarthritic pain in rat09/24/2019
- Original ArticleMicrobiological and Physicochemical Stability of OXYCODONE HYDROCHLORIDE (cas 124-90-3) Solutions for Patient-Controlled Delivery Systems09/10/2019
- Original research articlePharmacokinetics of OXYCODONE HYDROCHLORIDE (cas 124-90-3) and three of its metabolites after intravenous administration in Chinese patients with pain09/09/2019
-
Health and Chemical more >